SCHEMBL6496010

SCHEMBL6496010

COc1ccc(-c2cc3cc(F)c(F)cc3[nH]2)cc1NS(=O)(=O)c1cccc(C#N)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 7/20 0.63
TRIM24 O15164 1/20 0.50
MAPT P10636 1/20 0.50
PIK3CD O00329 1/20 0.48
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HTR6 P50406 1/20 0.44
KIT P10721 1/20 0.42
BRAF P15056 1/20 0.42
FRK P42685 1/20 0.42
SIK1 P57059 1/20 0.42
MAP2K5 Q13163 1/20 0.42
AURKB Q96GD4 1/20 0.42
SRMS Q9H3Y6 1/20 0.42
MAP3K20 Q9NYL2 1/20 0.42
GLO1 Q04760 1/20 0.42
SLC40A1 Q9NP59 1/20 0.42
ALOX15 P16050 1/20 0.41
CRBN Q96SW2 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6502511 0.87 ACLY (0.46) ACLYALOX15
Hydrochloric Acid SCHEMBL6501856 0.86 ACLY (0.45) ACLYALOX15
SCHEMBL6502189 0.84 HPGD (0.53) ACLYALDH1A1HTR6
SCHEMBL6502463 0.82 ACLY (0.59) ACLYMAPTALDH1A1
SCHEMBL6502495 0.81 ACP1 (0.44) ACLYMAPTKDM4EALDH1A1ALOX15
SCHEMBL6503424 0.80 ALOX15 (0.44) ACLYMAPTPIK3CDKITALOX15
SCHEMBL6527791 0.79 ALOX15 (0.44) ACLYMAPTALOX15
SCHEMBL21999602 0.78 ACLY (1.00) ACLYTRIM24MAPTPIK3CD
SCHEMBL7113047 0.78 ALOX15 (0.45) ACLYMAPTALOX15
SCHEMBL6803530 0.77 ALDH1A1 (0.55) ACLYALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6858739-B2 Indole and benzimidazole 15-lipoxygenase inhibitors WARNER-LAMBERT COMPANY (US) 2005-02-22 US claimed
EP-1294686-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-03-26 EP claimed
WO-2001096299-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6858739-B2 Indole and benzimidazole 15-lipoxygenase inhibitors WARNER-LAMBERT COMPANY (US) 2005-02-22 US disclosed
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors CONNOR DAVID THOMAS (US) 2004-02-26 US disclosed
EP-1294686-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-03-26 EP disclosed
WO-2001096299-A2 INDOLE DERIVATIVES AND THEIR USE AS 15-LIPOXYGENASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038943-A1 Indole and benzimidazole 15-lipoxygenase inhibitors ALOX15, ALOX5, ALOX12 ACLY 3409/4885TRIM24 1350/4885MAPT 4865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.